The Expression Profiles of lncRNAs Are Associated with Neoadjuvant Chemotherapy Resistance in Locally Advanced, Luminal B-Type Breast Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25158077 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Miguel González-Woge und 18 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, Universidad Nacional Autónom…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Breast Neoplasms, Drug Resistance, Neoplasm, Neoadjuvant Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Ciencia, Humanidades y Tecnología (CONHACYT), National Cancer Institute of Mexico, CONACYT.
Themen: Onkologische Pflege
Abstract (Originalsprache)
lncRNAs are noncoding transcripts with tissue and cancer specificity. Particularly, in breast cancer, lncRNAs exhibit subtype-specific expression; they are particularly upregulated in luminal tumors. However, no gene signature-based laboratory tests have been developed for luminal breast cancer identification or the differential diagnosis of luminal tumors, since no luminal A- or B-specific genes have been identified. Particularly, luminal B patients are of clinical interest, since they have the most variable response to neoadjuvant treatment; thus, it is necessary to develop diagnostic and predictive biomarkers for these patients to optimize treatment decision-making and improve treatment quality. In this study, we analyzed the lncRNA expression profiles of breast cancer cell lines and patient tumor samples from RNA-Seq data to identify an lncRNA signature specific for luminal phenotypes. We identified an lncRNA signature consisting of LINC01016, GATA3-AS1, MAPT-IT1, and DSCAM-AS1 that exhibits luminal subtype-specific expression; among these lncRNAs, GATA3-AS1 is associated with the presence of residual disease (Wilcoxon test, p < 0.05), which is related to neoadjuvant chemotherapy resistance in luminal B breast cancer patients. Furthermore, analysis of GATA3-AS1 expression using RNA in situ hybridization (RNA ISH) demonstrated that this lncRNA is detectable in histological slides. Similar to estrogen receptors and Ki67, both commonly detected biomarkers, GATA3-AS1 proves to be a suitable predictive biomarker for clinical application in breast cancer laboratory tests.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Avenida San Fernando No. 22 Col. Sección XVI, Tlalpan, Me…
- Posgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Unidad de Posgrado, Edificio D, 1° Piso, Circuito de Posgrados, Ciudad Universitaria, Coyoacán, Mexico City C. P. 04510, Mexico.
- Departamento de Oncología Médica de Mama, Instituto Nacional de Cancerología, Tlalpan, Mexico City C. P. 14080, Mexico.
- Departamento de Tumores Mamarios, Instituto Nacional de Cancerología, Avenida San Fernando No. 22 Col. Sección XVI, Tlalpan, Mexico City C. P. 14080, Mexico.
- Genomics Laboratory, Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Tlalpan, Mexico City C. P. 14080, Mexico.
- Clínica de Cáncer Hereditario, Instituto Nacional de Cancerología, Avenida San Fernando No. 22 Col. Sección XVI, Tlalpan, Mexico City C. P. 14080, Mexico.
ORCID-Profile: Miguel González-Woge, Laura Contreras-Espinosa, José Antonio García-Gordillo, Paula Cabrera-Galeana, Rosa Rebollar-Vega, Clementina Castro-Hernández, José Díaz-Chávez, Cristian Arriaga-Canon, Luis Alonso Herrera
Förderung
- Consejo Nacional de Ciencia, Humanidades y Tecnología (CONHACYT)
- National Cancer Institute of Mexico
- CONACYT
Zitieren
APA
González-Woge, M., Contreras-Espinosa, L., García-Gordillo, J. A., Aguilar-Villanueva, S., Bargallo-Rocha, E., Cabrera-Galeana, P., Vasquez-Mata, T., Cervantes-López, X., Vargas-Lías, D. S., Montiel-Manríquez, R., Bautista-Hinojosa, L., Rebollar-Vega, R., Castro-Hernández, C., Álvarez-Gómez, R. M., De La Rosa-Velázquez, I. A., Díaz-Chávez, J., Jiménez-Trejo, F., Arriaga-Canon, C., & Herrera, L. A. (2024). The Expression Profiles of lncRNAs Are Associated with Neoadjuvant Chemotherapy Resistance in Locally Advanced, Luminal B-Type Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158077
Vancouver
González-Woge M, Contreras-Espinosa L, García-Gordillo JA, Aguilar-Villanueva S, Bargallo-Rocha E, Cabrera-Galeana P, et al. The Expression Profiles of lncRNAs Are Associated with Neoadjuvant Chemotherapy Resistance in Locally Advanced, Luminal B-Type Breast Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158077
BibTeX
@article{GonzlezWoge2024,
author = {González-Woge, Miguel and Contreras-Espinosa, Laura and García-Gordillo, José Antonio and Aguilar-Villanueva, Sergio and Bargallo-Rocha, Enrique and Cabrera-Galeana, Paula and Vasquez-Mata, Tania and Cervantes-López, Ximena and Vargas-Lías, Diana Sofía and Montiel-Manríquez, Rogelio and Bautista-Hinojosa, Luis and Rebollar-Vega, Rosa and Castro-Hernández, Clementina and Álvarez-Gómez, Rosa María and De La Rosa-Velázquez, Inti Alberto and Díaz-Chávez, José and Jiménez-Trejo, Francisco and Arriaga-Canon, Cristian and Herrera, Luis Alonso},
title = {The Expression Profiles of lncRNAs Are Associated with Neoadjuvant Chemotherapy Resistance in Locally Advanced, Luminal B-Type Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25158077}
}
EUVIMED